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Abstract: Impaired autophagic and proteasomal cleansing have been documented in aged retinal
pigment epithelial (RPE) cells and age-related macular degeneration (AMD). Omega-3 fatty acids
and resveratrol have many positive homeostatic effects in RPE cells. In this work, ARPE-19 cells were
treated with 288 ng of Resvega, containing 30 mg of trans resveratrol and 665 mg of omega-3
fatty acids, among other nutrients, with proteasome inhibitor MG-132 or autophagy inhibitor
bafilomycin A1 up to 48 h. Autophagy markers p62/SQSTM1 (p62) and LC3 (microtubule-associated
protein 1A/1B-light chain 3) were analyzed by Western blotting. Fluorescence microscopy with
mCherry-GFP-LC3 plasmid was applied to study the autophagy flux, and cytoprotective effects were
investigated with colorimetric MTT and LDH assays. Resvega induced autophagy by showing
increased autolysosome formation and autophagy flux, and the change in the p62 and LC3
protein levels further confirmed the fluorescent microscopy results. Moreover, Resvega provided
a clear cytoprotection under proteasome inhibition. These findings highlight the potential of the
nutraceuticals containing resveratrol, omega-3 fatty acids and other nutrients in the prevention of
ARPE-19 cell damage.
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1. Introduction
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness among
the elderly in Western countries. The number of patients suffering from AMD is expected to multiply
over the coming decades. AMD has a significant impact on the lives of patients due to the impairment
of sharp and color vision that disturbs daily life; for example, face recognition and reading [1]. The
direct medical costs of AMD treatment amount to billions of dollars in the U.S. alone, and tens of
millions of dollars in European countries, making it a financial burden for public health services [2].
AMD can be divided into dry and wet forms with ~80% and ~20% prevalence, respectively. Currently,
there are no effective treatments for dry AMD. The wet form of AMD can be treated with anti-vascular
endothelial growth factor (anti-VEGF) injections, but this treatment only delays the progression of
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the disease. Therefore, there is a need for new preventive and medicinal approaches and therapies
targeted against AMD.
AMD is characterized as progressive loss of central vision with degenerative and neovascular
changes in the retina [1]. The etiology of AMD is multifactorial and includes genetic susceptibility,
smoking, obesity, arteriosclerosis, hypertension, and unhealthy diet [3]. The cellular pathology of AMD
coincides with oxidative stress, inflammation and protein aggregation [4,5]. The post-mitotic retinal
pigment epithelial (RPE) cells are responsible for the maintenance of the retina by uptaking nutrients
and removal of waste material, such as the outer segments of photoreceptor cells responsible for
visual perception [6]. The role of RPEs as a “janitor” of the retina includes the maintenance of protein
homeostasis by various mechanisms including two proteolytic pathways: the ubiquitin-proteasome
system (UPS) and the lysosomal/autophagosomal degradation system (autophagy) [7]. The UPS is
responsible for the degradation of 80%–90% of proteins, mostly short-lived or damaged proteins [8].
Autophagy is specialized to degrade aggregated proteins and cell organelles. Inefficient protein
homeostasis affects the capability of the cell to tolerate stress, and vice versa. This can result in
detrimental accumulation of lipid and protein aggregates, lipofuscin and drusen, which is a hallmark
of AMD [9,10]. The number of aggregated proteins is increased by oxidative stress, making the
autophagosomal degradation pathway greatly important [11]. Oxidative stress is known to be high in
the macular area of the retina and, when chronic, it can overwhelm the RPE cells and cause loss of RPE
and photoreceptor cells—the initial step of AMD pathology.
In autophagy, the ubiquitin-binding p62/SQSTM1 (p62) protein serves as a marker for the
cargo that is subjected to autophagosomal degradation. The protein level of p62 may increase
shortly after autophagy activation, but its content decreases over time in the autophagic degradation
process along with the cargo [12]. The p62-marked cargo is then engulfed by the double-membrane
organelle—the autophagosome—guided by p62-LC3 (microtubule-associated protein 1A/1B-light
chain 3) interaction [13]. The LC3 protein has two forms, LC3-I and LC3-II: the LC3-I form is
found in pre-autophagosomal structures and is converted to the LC3-II form in the autophagosome
maturation process by phosphatidylethanolamine (PE) conjugation. After the cargo is isolated
in the autophagosome, a lysosome is fused to form an autolysosome. Finally, the cargo and the
inner membrane of the autophagosome and the lysosome are degraded by lysosomal hydrolytic
enzymes [14].
The use and research of naturally-derived compounds for preventing and treating age-related
diseases associated with autophagy and oxidative stress has grown over the past decade [15–18].
Growing evidence of stilbene compound’s ability to decrease oxidative stress [19,20] and ameliorate
oxidative stress-related diseases [21] has drawn attention to autophagy research. Current data indicate
that the key regulator of the oxidative stress defense system, nuclear factor-erythroid 2-related
factor-2 (Nrf2) interacts closely with the autophagy process via the p62 protein [22]. Furthermore,
the key regulator of autophagy, AMP-activated protein kinase (AMPK), has been shown to induce
Nrf2-mediated protection against oxidative stress [23]. It is possible that stilbene compounds
have a dual role in oxidative stress related diseases, activation of the antioxidant defense system,
and autophagy.
Recently, resveratrol, a natural polyphenolic compound found mainly in grapes, peanuts, and
berries, based on an oral supplement produced long-term beneficial effects on visual function in
human patients [24]. Furthermore, resveratrol protected RPE cell lines from UV-induced oxidative
stress [25] and suppressed VEGF expression in human RPE cells and, together with omega-3 fatty
acids, in a mouse model of choroidal neovascularization [26,27], prevented the development of
AMD. Docosahexaenoic acid (DHA), which is an omega-3 polyunsaturated fatty acid, has shown to
induce autophagy in human retinal pigment epithelial cells (ARPE-19) and human cancer cells [28,29].
The Age-Related Eye Disease Study (AREDS) [30,31] demonstrated that the combination of an oral
supplement consisting of antioxidant vitamins C (500 mg), E (400 international units), and β-carotene
(15 mg), minerals (zinc (60 mg of zinc oxide) with copper (2 mg cupric oxide)) reduced the risk of
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intermediate AMD developing to advanced AMD by 25%. Furthermore, the risk of moderate vision
loss was decreased by 19% in a five-year follow-up.
In this article, a commercial supplement (Resvega, formulated by Laboratoires Théa using the
results from the AREDS study) was given to RPE cell lines; protein levels of p62, LC3-I/LC3-II,
cytoprotective effects, and the number of autolysosomes were investigated to determine the activation
of autophagy.
2. Materials and Methods
2.1. Cell Culture
The ARPE-19 cell line from American Type Culture Collection (ATCC, Manassas, VA, USA) was
used in the experiments. The cells were grown in Dulbecco’s modified eagle medium/nutrition mix
F12 (1:1 Gibco, Paisley, UK) with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA), 100 µg/mL
streptomycin (Lonza, Walkersville, MD, USA), 100 U/mL penicillin (Lonza) and 2 mM L-glutamine
(Lonza) unless otherwise stated. The cells were grown at 37 ˝C in a humidified 5% CO2 atmosphere.
Cells with passage numbers under 15 were being used.
2.2. Treatments
To study the effects of Resvega (Laboratoires Théa, Clermont-Ferrand, France) to induce
autophagy, ARPE-19 cells were incubated in medium containing 288 ng Resvega corresponding
to 25 µM of resveratrol (contents: 30 mg of trans resveratrol as a daily dose, 240 mg of vitamin C,
30 mg of vitamin E, 12.5 mg of zinc, 1 mg of copper, 665 mg of omega-3 fatty acids, 10 mg of lutein,
and 2 mg of zeaxanthin), 1 µM proteasome inhibitor MG-132 (Calbiochem, Billerica, MA, USA), and
50 nM autophagy inhibitor bafilomycin A1 (Sigma-Aldrich, St. Louis, MO, USA). Approximately
250,000 cells/well were seeded in 12-well plates and incubated for 48 h to reach confluency. The
old medium was removed and fresh medium containing Resvega, MG-132, bafilomycin A1, or their
combinations diluted in dimethyl sulfoxide (DMSO) was added to the cell culture for 6–48 h. Control
samples were treated with the same amount of DMSO found in the Resvega treatment samples
(0.35% v/v). The treatments were also conducted without serum to study Resvega’s ability to increase
starvation-induced autophagy in the ARPE-19 cell line. The serum-free cells were washed once with
serum-free medium before treatment and another dose of compounds was added by changing fresh
serum-free medium after 24 h of incubation to achieve cytotoxic effects by proteasome inhibition.
Otherwise, the cells were treated as described above.
2.3. Western Blot Analyses of Autophagy Markers p62 and LC3-I/LC3-II
ARPE-19 cells were lysed with Mammalian Protein Extraction Reagent (M-PER, Thermo scientific,
Rockford, IL, USA). Cells were washed twice with PBS (Dulbecco’s phosphate-buffered saline,
Sigma-Aldrich) and then 75 µL of M-PER solution was added to each well for 3 min. The wells
were scraped on ice and the lysates were collected and centrifuged at 13,000ˆ g for 5 min at 4 ˝C. The
protein content was measured using a Bradford protein assay from the supernatant. 20 µg of proteins
were separated on 15% SDS-PAGE and transferred to a nitrocellulose membrane (Amersham Protran
premium 0.45 µm NC, GE Healthcare, Germany). The membranes were blocked with 3% skim milk in
0.3% Tween PBS for 1.5 h. p62 primary antibody (sc-28359, Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) was diluted 1:1000 with 0.5% bovine serum albumin (BSA) in 0.3% Tween PBS and incubated
over night at 4 ˝C. LC3-I/LC3-II primary antibody (#3868, Cell Signaling Technology, Danvers, MA,
USA) was diluted 1:1000 with 5% BSA in 0.1% Tween Tris-buffered saline (TBS) and incubated over
night at 4 ˝C, whereas alpha-Tubulin primary antibody (#T5168, Sigma-Aldrich, Saint Louis, MO,
USA) was diluted 1:8000 with 1% skim milk in 0.05% Tween PBS for 15 min at room temperature. The
secondary antibody for p62 and alpha-Tubulin was horseradish peroxidase (HRP)-linked anti-mouse
(NA931, GE Healthcare) diluted 1:10,000 with 3% skim milk in 0.3% Tween PBS for 2 h at room
Nutrients 2016, 8, 284 4 of 13
temperature and 1% skim milk in 0.05% Tween PBS for 15 min at room temperature, respectively. The
secondary antibody for LC3-I/LC3-II was HRP-linked anti-rabbit (Novex™, #A16014, ThermoFisher
Scientific, Rockford, IL, USA) diluted 1:10,000 with 3% skim milk in 0.1 Tween TBS for 2 h at room
temperature. The membranes were washed after primary and secondary antibody incubation with
0.3% Tween in PBS (p62), 0.1% Tween in TBS (LC3-I/LC3-II) or 0.05% Tween in PBS (alpha-Tubulin).
After secondary incubation, the bands were visualized using Immobilon Western Chemiluminescent
HRP Substrate (Millipore, Billerica, MA, USA) and an ImageQuant RT ECL system (GE Healthcare,
Little Chalfont, UK). The band quantification was performed using ImageJ software (National Institutes
of Health, Bethesda, MD, USA) and the band intensities of p62 and LC3-I/LC3-II were normalized
against alpha-Tubulin.
2.4. Cell Viability Assays
Cell viability from serum-free samples were analyzed using a 3-(4,5 dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assay [32] after 48 h of proteasome inhibition and/or Resvega
incubation. The absorbance of lysate was measured in a spectrophotometer (Model 550 Microplate
reader, BIO-RAD, USA) at 550 nm. The condition of the cells was assessed with a microscope before
MTT assay to confirm the correlation of absorbance readings. Samples from the growth medium were
taken for the lactate dehydrogenase (LDH) assay (CytoTox 96® Non-Radioactive Cytotoxicity Assay,
Promega, Madison, WI, USA) before the MTT-assay. 50 µL of growth medium from each sample was
added to a 96-well flat bottom microtiter plate and 50 µL of LDH assay buffer was added and gently
mixed. The plate was kept in the dark for 30 min before adding 50 µL of stop solution. After addition
of the stop solution, the plate was gently mixed and absorbance was recorded at 490 nm.
2.5. Determination of Lysosome Fusion to the Autophagosome Using mCherry-GFP-LC3-Plasmid
Thirty-five thousand cells were plated to a Permanox eight-well chamber slide (#177445, Thermo
Scientific Nunc®, Waltham, MA, USA) and incubated for 24 h. After reaching ~50%–60% confluency,
cells were transfected with 500 ng/well of pH sensitive tandem mCherry-GFP-LC3-plasmid (kind
gift from Drs Ana Maria Cuervo and Hiroshi Koga) using ExGen 500 in vitro transfection reagent
(Fermentas, Burlington, ON, Canada). 24 h after transfection, cells were treated with 36 ng Resvega
(corresponding the concentration used in the Western blot experiments) and/or MG-132 for 12 h.
The control cells were treated with the same amount of DMSO found in the treatments. The cells
were then fixed with 4% paraformaldehyde (PFA) for 15 min and the nuclei stained with DAPI
1:10,000 (41,6-diamidino-2-phenylindole, Sigma-Aldrich) for 5 min. The cells were photographed using
fluorescence microscopy (Axio Imager with ApoTome.2 (Carl Zeiss, Oberkochen, Germany) with Carl
Zeiss ZEN imaging software) within 24 h. The samples were masked from the photographer. At neutral
pH, both of the fluorophores fluoresce, indicating autophagosome presence (yellow), when a lysosome
gets fused to an autophagosome during autolysosome maturation, the result is a lower pH and
quenching of the GFP signal, which is seen as red fluorescence only (autolysosome). Autophagosome
and autolysosome dots were then counted using ImageJ software.
2.6. Statistical Analyses
Data are presented as mean ˘ standard deviation (SD) (n = 3) for the Western blotting and cell
viability experiments, and as mean ˘ standard error of the mean (SEM), (n = 9–12) for the fluorescence
microscopy experiment. Statistical analyses were done using IBM SPSS Statistics software version 21
(IBM, Armonk, NY, USA). All of the data were subjected to one-way analysis of variance (ANOVA),
followed by Tukey’s test for multiple comparison (p values < 0.05 were considered significant).
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3. Results
3.1. Resvega Alters the Level of Autophagy Markers p62 and LC3
ARPE-19 cells were treated with Resvega for 6 h, 12 h, and 48 h. Protein levels of autophagy
markers p62 and LC3 were analyzed at each time point to study the activation of autophagy. Western
blot data showed a mild increase in p62 content after Resvega treatment for 6 h and 12 h, the p62
level being significantly higher after Resvega treatment for 48 h (approximately nine-fold increase vs.
control) (Figure 1A). The LC3-II protein level showed slight increase after 6 h of Resvega treatment,
but decreased to baseline levels at 12 h and 48 h (Figure 1B). The protein expression of LC3-I was
also decreased by Resvega treatment at 12 h, possibly due to the conversion of LC3-I to LC3-II in the
autophagosome maturation (Figure 1B). The levels of LC3-I remained unchanged at 6 h and 48 h.
3.2. Resvega Faciliates Protein Clearance by Autophagy in Proteasome Inhibition Model
The ARPE-19 cells were treated with MG-132, a proteasome inhibitor, to create protein cargo for
the autophagic machinery [33,34]. The MG-132 treatment significantly increased the protein level of
p62 at all time points as expected, whereas simultaneous treatment with Resvega and MG-132 showed
~33% lower p62 content after 48 h (Figure 1A). The protein level of LC3-II was significantly increased
by MG-132 treatment at all time points (Figure 1B), while simultaneous treatment with Resvega and
MG-132 resulted in significantly lower LC3-II expression at 12 h. MG-132 treatment increased the
LC3-I protein levels at 48 h, while at other time points, the LC3-I protein levels resembled the results
obtained with Resvega alone (Figure 1B).
Figure 1. Cont.
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Figure 1. ARPE-19 cells were treated with 288 ng Resvega, 1 µM MG-132 or their combination for
6 h, 12 h, and 48 h in normal growth conditions. The protein level of p62 (A) and LC3-I/LC3-II
(B) were analyzed by Western blot, while the expression was quantified in a comparison to
α-tubulin and presented as fold change compared to control; and (C) cells were transfected with
mCherry-GFP-LC3-plasmid and treated for 12 h, the fluorescence was then determined by fluorescence
microscopy, red (autolysosomes) and yellow (autophagosomes) dots were counted and presented as
the percentage of autolysosomes. Scale bar: 5 µm. Western blotting data are shown as mean ˘ SD
(n = 3), and the percentage of autolysosomes is shown as mean ˘ SEM (n = 9–12). * p < 0.05, ANOVA.
3.3. Resvega Induces Autophagic Flux by Increasing the Number of Autolysosomes
ARPE-19 cells were transfected with pH-sensitive mCherry-GFP-LC3-plasmid to monitor
autophagic flux [35]. The cells were then treated with Resvega and/or MG-132 with the
mCherry-GFP-LC3-plasmid for 12 h and analyzed with fluorescence microscopy to investigate
autolysosome formation. Resvega treatment clearly elevated the portion of autolysosomes compared
to control (Figure 1C). MG-132 treatment appeared to slightly elevate the portion of autolysosomes,
whereas treatment with Resvega and MG-132 together elevated the portion of autolysosomes
significantly when compared to MG-132 treatment. The observed changes in protein levels, such as a
decrease of LC3-II at 12 h, support the fluorescence microscopy findings.
3.4. Resvega Enhances Autophagy and Increases Cell Viability in the Starvation-Induced Autophagy Model
Serum starvation increases autophagy when the cell recycles necessary nutrients that are normally
provided in serum. ARPE-19 cells were treated in a starvation-induced autophagy model with Resvega
and/or MG-132 proteasome inhibitor for 6 h, 12 h, and 48 h. Protein levels of p62 and LC3 were
analyzed by Western blotting. When autophagy was already heavily activated by serum starvation,
Resvega and/or MG-132 elevated the expression of p62 significantly at 6 h and 12 h, whereas Resvega
treatment alone maintained high p62 levels at 48 h (Figure 2A). Resvega, together with MG-132,
increased p62 content more than MG-132 alone at 6 h and 12 h. The protein levels of LC3-II were
elevated by Resvega and/or MG-132 treatment at 6 h, however, at 12 h the LC3-II content decreased
back to the baseline level and was below the baseline level obtained with Resvega (Figure 2B). Only
the combined treatment of Resvega and MG-132 maintained high LC3-II levels after 12 h of treatment.
At 48 h, MG-132 alone and Resvega + MG-132 both showed elevated levels of LC3-II. The highest
LC3-II content was found with Resvega + MG-132. The levels of LC3-I were significantly higher with
Resvega + MG-132 treatment at 12 h, whereas lower levels of LC3-I were observed with Resvega alone
(Figure 2B). After 48 h of treatment, Resvega alone and Resvega + MG-132 clearly showed decreased
levels of LC3-I. The decrease of LC3-I together with the increase of LC3-II can be explained by the
conversion of LC3-I to LC3-II when autophagy is induced.
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Figure 2. ARPE-19 cells were treated with 288 ng of Resvega, 1 µM MG-132 or their combination
for 6 h, 12 h, and 48 h under serum starvation. The protein levels of p62 (A) and LC3-I/LC3-II
(B) were analyzed by Western blot, while the expression was quantified in comparison to α-tubulin
and presented as a fold change compared to control; the cells were treated for 48 h and MTT (C) and
LDH (D) assays were performed. Western blot data are shown as mean ˘ SD (n = 3), MTT assay data
as mean percentage (control = 100%) ˘ SD (n = 3) and LDH assay data as mean absorbance ˘ SD
(n = 3). * p < 0.05, ANOVA.
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Figure 3. ARPE-19 cells were treated with 288 ng Resvega, 50 nM bafilomycin A1, or their combination
for 12 h (A) in normal growth conditions and (B) a starvation-induced autophagy model. The protein
level of p62 and LC3-I/LC3-II were analyzed by Western blot, while the expression was quantified in a
comparison to α-tubulin and presented as a fold change compared to control. Western blotting data
are shown as mean ˘ SD (n = 3). * p < 0.05, ANOVA.
The LDH release, a biomarker for cytotoxicity and cytolysis, and MTT assay measuring the
function of mitochondria were performed for the serum starvation-induced autophagy model to
monitor toxic effect of protein accumulation via proteasome inhibition by MG-132. These protein
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aggregates can be removed via autophagosomal degradation and the possible alleviation of this stress
can be monitored with cytotoxicity assays. Resvega itself did not increase the levels of LDH release nor
decreased cell viability in the MTT assay; MG-132 showed clear cytotoxic effects with both methods
after 48 h of treatment (Figure 2C,D). Resvega was able to alleviate the cytotoxic effects of MG-132,
possibly by inducing autophagy.
3.5. Resvega Induces Accumulation of LC3 and p62 under Autophagy Inhibition
ARPE-19 cells were treated with bafilomycin A1, an inhibitor of vacuolar type H(+)-ATPase,
preventing the acidification of lysosomes and formation of autolysosomes, for 6 h and 12 h to investigate
effects of Resvega on the accumulation of LC3-II or p62. The bafilomycin treatment significantly
increased the protein levels of LC3-II and p62 at both time points as a result of autophagy inhibition
(Figure 3 and supplementary materials Figure S1), whereas simultaneous treatment with Resvega and
bafilomycin showed significant accumulation of LC3-II and p62 in a starvation-induced autophagy
model at 6 h (supplementary materials Figure S1). After 12 h of treatment, the protein levels of LC3-II
and p62 also increased significantly in normal growth conditions (Figure 3A). The accumulation of
LC3-II and p62 continued in the starvation-induced autophagy model at 12 h (Figure 3B). Interestingly,
the amount of LC3-I was decreased and the LC3-II was increased at 12 h in normal growth conditions
that resemble the results obtained with the proteasome inhibitor MG-132 (Figure 1B). The accumulation
rate of LC3-II and p62 are in correlation with the results obtained by Resvega alone when comparing
normal growth conditions and the starvation-induced autophagy model (Figures 1 and 2).
4. Discussion
In this study, Resvega was able to activate autophagic machinery and further increase autophagy
in the starvation model. Moreover, Resvega contributed to the survival of ARPE-19 cells exposed to
detrimental protein waste triggered by proteasome inhibition.
The p62 protein is the key regulator of autophagy, binding to protein aggregates and guiding them
into autophagosomal degradation. Macula samples from human AMD patients show accumulation of
p62, suggesting declined autophagosomal degradation and highlighting the importance of autophagy
in AMD [33]. Classically, during autophagy, the p62 level is expected to decrease due to degradation
during the autophagic process, as shown with resveratrol [36,37]. However, in our study, the level
of p62 increased under Resvega treatment after 6 h and continued to increase during the monitored
time period. Resvega contains omega-3 fatty acids, and marine omega-3 polyunsaturated fatty acids
that have been shown to increase the amount of p62 in ARPE-19 cell lines, which might enhance the
selectivity of damaged or aggregated proteins towards autophagy [28,38]. Moreover, the increase in
the p62 protein level with Resvega might be explained by the lack of protein substrate for autophagy,
whereas proteasome inhibition with MG-132 provides the necessary protein substrate and explains
the decrease of p62. The behavior of p62 was similar in the starvation model with the exception that
treatments, especially with Resvega, had a greater effect when autophagy was activated. Interestingly,
p62 levels returned to baseline after proteasome inhibition for 48 h, indicating active removal of
protein waste.
Resvega significantly increased the level of LC3-II after 6 h of treatment indicating an enhancement
of autophagosome formation and packaging of waste material for autophagic degradation. However,
the level of LC3-II had decreased to below the baseline level after 12 h of treatment. This could be
another sign of autophagy activation since autophagosomes, with LC3-II in the membrane structures,
are degraded during the autophagy process [13]. Similar results with LC3-II levels using resveratrol
have been seen with human dermal fibroblasts and human umbilical vein endothelial cells [39,40].
The LC3-II levels were also significantly increased by the proteasome inhibitor MG-132, indicating
autophagosome formation. However, only co-treatment with Resvega led to decreased LC3-II levels
at 12 h, probably due to further enhanced autophagic flux. The level of LC3-I supports this theory
since the LC3-I level was significantly decreased at the same time point, possibly due to conversion
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of LC3-I to LC3-II in the autophagosome maturation process. In the starvation model, the LC3-II
levels were increased by Resvega, MG-132, and their combination after 6 h of treatment. Six hours
later, only co-treatment maintained high levels of LC3-II, suggesting further induced autophagosome
formation by Resvega. Interestingly, the levels of LC3-II were also high at 48 h, despite normal p62
levels. Apparently, cells were able to remove excess proteins by autophagy, resulting in increased
LC3-II levels, yet maintaining baseline p62 levels. Another interesting result is the level of LC3-I, which
was decreased significantly by co-treatment than by MG-132 alone, at 48 h. This may indicate better
LC3-II conversion and, perhaps, more efficient autophagy. Autophagy inhibition with bafilomycin
showed high accumulation of both LC3-II and p62 in Resvega treated samples implicating Resvega’s
ability to induce autophagy without the presence of proteasome inhibition or any other treatment such
as starvation.
The use of mCherry-GFP-LC3 plasmid for monitoring the number autophagosomes and
autolysosomes further confirmed the results observed from Western blotting. The percentage of
lysosomes in Resvega treated samples was significantly higher compared to control and MG-132
samples. However, the proteasome inhibition increased not only the number of autolysosomes but also
the number of autophagosomes (data not shown). This could be a result of inefficient autophagic flux
where autophagic machinery is overwhelmed with waste proteins caused by proteasome inhibition.
As a result, the rate of autophagic flux is not efficient and autophagosomes start to accumulate.
Co-treatment with Resvega facilitated the autophagic flux and accumulation of autophagosomes was,
therefore, not observed.
LDH and MTT cell viability tests confirmed the capability of Resvega to protect ARPE-19 cells
from harmful protein caused by proteasome inhibition. Similar results have been observed in human
neuroblastoma cells where resveratrol protected cells from rotenone-induced cell death by activating
autophagy and the antioxidant defense system [36]. In this experiment, the p62 and LC3-II levels
of MG-132 and MG-132 + Resvega samples were equal when cell viability tests were performed.
However, there was a clear difference in LDH and MTT assay data between MG-132 and MG-132 +
Resvega samples. In addition to the activation of autophagy, this could be explained by the concurrent
activation of antioxidant defense mechanisms [28]. It has been shown that p62 is closely involved in
the regulation of the Nrf2/ARE antioxidant defense pathway [22,41]. Moreover, resveratrol, which is
present in Resvega, can directly activate the Nrf2/ARE pathway [36]. When autophagy was inhibited
with bafilomycin, the accumulation of both p62 and LC3-II suggests that Resvega has a dual role as an
autophagy and Nrf2/ARE activator.
Resvega, a commercial supplement developed following the AREDS study, clearly activated
autophagy by modulating p62 and LC3 levels and by increasing the number of autolysosomes in
ARPE-19 cells. However, other models, such as stem cells, primary cells, and human materials
are required to support these findings. As such, Resvega seems to be a promising supplement for
preventing and treating age-related diseases associated with impaired autophagy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/8/5/284/s1,
Figure S1, ARPE-19 cells were treated with 288 ng Resvega, 50 nM bafilomycin A1 or their combination for 6 h
(A) in normal growth conditions and (B) starvation-induced autophagy model. The protein level of p62 and
LC3-I/LC3-II were analyzed by Western blot, while the expression was quantified in a comparison to α-tubulin
and presented as fold change compared to control. Western blotting data are shown as mean ˘ SD (n = 3).
* p < 0.05, ANOVA.
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